Lifecore Biomedical, Inc. (LFCR) stock
LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
$6.42+0.02 (+0.31%)
Close on Nov 13, 2026Market cap $243.02MP/E –Yield –
Lifecore Biomedical r&d expenses
Research and development expenses are spending on new products and technology.
Lifecore Biomedical's R&D Expenses for the twelve months ending May 25, 2025 was $8.26M, down 3.7% year over year. For fiscal 2025 it was $8.26M, down 3.7% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $12.80M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | May 25, 2025 | $8.26M | -3.7% |
| FY2024 | May 26, 2024 | $8.58M | -1.8% |
| FY2023 | May 28, 2023 | $8.74M | +11.4% |
| FY2022 | May 29, 2022 | $7.84M | +17.3% |
| FY2021 | May 30, 2021 | $6.68M | -11.8% |
| FY2020 | May 31, 2020 | $7.58M | -33.9% |
| FY2019 | May 26, 2019 | $11.47M | -10.4% |
| FY2018 | May 27, 2018 | $12.80M | +35.1% |
| FY2017 | May 28, 2017 | $9.47M | +31.1% |
| FY2016 | May 29, 2016 | $7.23M | +3.4% |
| FY2015 | May 31, 2015 | $6.99M | -3.0% |
| FY2014 | May 25, 2014 | $7.20M | -22.5% |
| FY2013 | May 26, 2013 | $9.29M | -3.4% |
| FY2012 | May 27, 2012 | $9.63M | +3.8% |
| FY2011 | May 29, 2011 | $9.28M | +112.7% |
| FY2010 | May 30, 2010 | $4.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2027CQ1 2026 | Sep 30, 2026 | $1.42M | -35.0% |
| Q4 FY2025CQ2 2025 | May 25, 2025 | $2.10M | -2.7% |
| Q3 FY2025CQ1 2025 | Feb 23, 2025 | $2.05M | -5.8% |
| Q2 FY2025CQ4 2024 | Nov 24, 2024 | $1.92M | -8.3% |
| Q1 FY2025CQ3 2024 | Aug 25, 2024 | $2.19M | +1.9% |
| Q4 FY2024CQ2 2024 | May 26, 2024 | $2.16M | +2.2% |
| Q3 FY2024CQ1 2024 | Feb 25, 2024 | $2.17M | -2.9% |
| Q2 FY2024CQ4 2023 | Nov 26, 2023 | $2.10M | -3.6% |
| Q1 FY2024CQ3 2023 | Aug 27, 2023 | $2.15M | -2.9% |
| Q4 FY2023CQ2 2023 | May 28, 2023 | $2.12M | -0.1% |
| Q3 FY2023CQ1 2023 | Feb 26, 2023 | $2.23M | -0.9% |
| Q2 FY2023CQ4 2022 | Nov 27, 2022 | $2.18M | +29.6% |
| Q1 FY2023CQ3 2022 | Aug 28, 2022 | $2.21M | +30.9% |
| Q4 FY2022CQ2 2022 | May 29, 2022 | $2.12M | +82.3% |
| Q3 FY2022CQ1 2022 | Feb 27, 2022 | $2.25M | +37.7% |
| Q2 FY2022CQ4 2021 | Nov 28, 2021 | $1.68M | +5.6% |
| Q1 FY2022CQ3 2021 | Aug 29, 2021 | $1.69M | -2.9% |
| Q4 FY2021CQ2 2021 | May 30, 2021 | $1.16M | -57.1% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $1.64M | -40.4% |
| Q2 FY2021CQ4 2020 | Nov 29, 2020 | $1.59M | -43.6% |
| Q1 FY2021CQ3 2020 | Aug 30, 2020 | $1.74M | -38.4% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $2.71M | -21.7% |
| Q3 FY2020CQ1 2020 | Feb 23, 2020 | $2.75M | +0.3% |
| Q2 FY2020CQ4 2019 | Nov 24, 2019 | $2.82M | +14.0% |
| Q1 FY2020CQ3 2019 | Aug 25, 2019 | $2.82M | +1.1% |
| Q4 FY2019CQ2 2019 | May 26, 2019 | $3.46M | -3.8% |
| Q3 FY2019CQ1 2019 | Feb 24, 2019 | $2.74M | -12.0% |
| Q2 FY2019CQ4 2018 | Nov 25, 2018 | $2.48M | -26.6% |
| Q1 FY2019CQ3 2018 | Aug 26, 2018 | $2.79M | +2.6% |
| Q4 FY2018CQ2 2018 | May 27, 2018 | $3.60M | +1.1% |
| Q3 FY2018CQ1 2018 | Feb 25, 2018 | $3.11M | +54.6% |
| Q2 FY2018CQ4 2017 | Nov 26, 2017 | $3.37M | +71.6% |
| Q1 FY2018CQ3 2017 | Aug 27, 2017 | $2.72M | +40.3% |
| Q4 FY2017CQ2 2017 | May 28, 2017 | $3.56M | +95.9% |
| Q3 FY2017CQ1 2017 | Feb 26, 2017 | $2.01M | – |
| Q2 FY2017CQ4 2016 | Nov 27, 2016 | $1.97M | – |
| Q1 FY2017CQ3 2016 | Aug 28, 2016 | $1.94M | – |
| Q4 FY2016CQ2 2016 | May 29, 2016 | $1.82M | – |
See a number that looks wrong?